We aimed i) to determine the reliability and feasibility of FeNO home monitoring in adults with moderate-to-severe asthma and ii) to investigate the relationship between serial FeNO measurements and recognised biomarkers of eosinophilic airways disease in asthma, specifically sputum and blood eosinophil counts. We hypothesised that serial FeNO measurements would correlate more closely with other biomarkers of eosinophilic airways disease than one-off readings, and that there may be a temporal relationship between FeNO and other eosinophil markers.
In this pilot study we recruited 10 adults (age >18 years) with moderate-to-severe asthma (Global Initiative for Asthma treatment steps 3-5 [4] ), diagnosed by a specialist asthma physician in a secondary care setting, according to British Thoracic Society guidelines [5] . The study was approved by the National Research Ethics Committee -East Midlands Leicester, and all participants gave their written informed consent. The participant group comprised five men and five women with a mean±SD age of 64±5 years. All participants were treated with inhaled corticosteroids (800-2000 μg per day beclometasone dipropionate equivalent) and long-acting β 2 -agonists. Six patients received maintenance low-dose prednisolone (5-15 mg per day). Mean±SD post-bronchodilator forced expiratory volume in 1 s (FEV1) (% pred) was 71.4±24.2 with mean±SD bronchodilator reversibility of 9.3±11.2%. A previous history of atopy was documented in three patients. Geometric mean (95% confidence interval) sputum eosinophil count was 6.1% (1.7-22.2%) and blood eosinophil count was 0.18×10 9 cells·L −1 (0.07-0.46×10 9 cells·L
−1
).
Participants were recruited during the period from December 2013 -April 2014. They were each provided with a NObreath FeNO monitor (Bedfont Scientific, Maidstone, UK) and carefully instructed in its use. Participants were provided with a paper diary and asked to record three morning FeNO readings on a daily basis over a 56-day period. Participants attended study visits twice-weekly, at which time daily diaries were retrieved, a blood sample was drawn for measurement of eosinophil count, and sputum induction was performed (or a spontaneous sample obtained) [6] . Sputum cell counts were performed by an experienced technician.
Eight out of ten participants completed the study and good quality data were obtained in each case. The median missing data rate for home-monitored FeNO was 7.1% (range 2.7-14.3%). Home-monitored FeNO was repeatable, with a median intraclass correlation coefficient of triplicate measurements of 0.83 (range 0.78-0.92). Further analyses presented below utilise the average of the three daily FeNO measurements. Sputum samples were obtained and analysed successfully for 39 out of 40 study visits, with 36 of these being spontaneous samples.
In order to assess the relationship between FeNO and recognised biomarkers of eosinophilic airways disease, we constructed a linear mixed model (SPSS 20, IBM Corporation, Somers, New York, NY, USA) in which blood or sputum eosinophil count was the dependent variable and FeNO was specified as a fixed effect in the model. We specified an autoregressive covariance structure for the repeated measures of blood or sputum eosinophil count within each individual, since we observed that repeated measurements became less closely correlated with the passage of time. We performed our analysis using a range of lag periods and windows to determine 1) how changes in FeNO related temporally to changes in blood and sputum eosinophil counts, and 2) whether taking a moving average (window) of 3, 5, 7 or 9 consecutive days' FeNO readings could improve the correlation with blood and sputum eosinophil counts. Figure 1a -b show example data from a single individual, demonstrating the relationship between FeNO and sputum eosinophil count. Increasing the window width results in smoothing of the data, masking day-to-day variability in FeNO and allowing the underlying trends to be better seen. This is the first study to show that FeNO is a reliable and repeatable method of measuring eosinophilic airway inflammation at home in patients with asthma. Our results indicate that maximal changes in FeNO appear to lag behind changes in sputum and blood eosinophils by 1 and 5 days respectively. However, FeNO can still give a good insight into the current level of sputum eosinophils, particularly if a moving average of 5-7 consecutive days' measurements is used. It should be noted that most patients in this study were able to provide spontaneous sputum samples and did not require formal induction with nebulised hypertonic saline. While spontaneous and induced sputum are not exactly equivalent, previous studies have indicated that the cellular content does not differ significantly between the two methods of expectoration [7] .
The home monitoring approach has the advantage of patient convenience, as well as the potential for day-to-day adjustment of therapy or the detection and preventative treatment of incipient asthma exacerbations. HASHIMOTO et al. [8] recently performed a pragmatic randomised controlled trial in which an internet-based approach to oral corticosteroid tapering, incorporating domiciliary FeNO, was compared to a conventional approach. The internet algorithm was found to allow more rapid tapering of oral corticosteroids without any reduction in asthma control or quality of life. HONKOOP et al. [9] found that adjustment of inhaled corticosteroid therapy in primary care using a symptom plus FeNO-driven strategy reduced asthma medication use while sustaining asthma control and quality of life. MALERBA et al.
[10] found that titrating inhaled corticosteroids using a combination of FeNO and sputum eosinophils reduced exacerbation rates and asthma symptoms compared to a conventional strategy, without additional increases in inhaled corticosteroid doses.
In conclusion, serial FeNO measurements may identify airway inflammation within close temporal proximity to changes in conventional biomarkers of eosinophilic disease such as sputum eosinophil count, with the added value of being of point-of-care. Further prospective trials are required to assess if this approach can successfully predict exacerbations or be used to titrate therapy in adults with asthma. 
